Ho Maykin
Transaction: 05/27/2026
BUY
Change
+80,000
Price
$1.86
Filing
05/29/2026
Type
BUY
Neumora Therapeutics, Inc. Common Stock
NMRA • Biotechnology
$1.31
▼ -0.04 (-2.96%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$242.56M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 5.87Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:08 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.31
Change-2.96%
Shares Out185.16M
Market Cap$242.56M
Enterprise Value$126.07M
52W Range0.83 - 3.65
Beta2.78
P/E-1.14
P/B5.45
P/FCF-1.34
EV/EBITDA-0.60
EV/FCF-0.70
Price$1.31
Change-2.96%
Shares Out185.16M
Market Cap$242.56M
Enterprise Value$126.07M
52W Range0.83 - 3.65
Beta2.78
P/E-1.14
P/B5.45
P/FCF-1.34
EV/EBITDA-0.60
EV/FCF-0.70
Earnings Yield-87.71%
FCF Yield-74.42%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio5.87
Quick Ratio5.87
Target$4.50
Target Upside243.51%
Target Median$4.50
Target Range4.00 - 5.00
Volume1.13M
Avg Volume1.79M
EPS Surprise0.02
Investment DNA
How strong this company looks for long-term investors
45
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
80/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 5.87Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 9 analyst votes · 2026-09-05
72/100
Bullish
Bullish
6
Hold
1
Bearish
2
Price Target
2026-08-16
Low
$4.00
Mean
$4.50
Median
$4.50
High
$5.00
Insider Transactions
Recent executive and insider activity
⚠ 2 high-volume insider sells detected
Halawa Alaa
Transaction: 05/27/2026
BUY
Change
+80,000
Price
$1.86
Filing
05/29/2026
Type
BUY
Piacquad David
Transaction: 05/27/2026
BUY
Change
+80,000
Price
$1.86
Filing
05/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Ho Maykin | BUY | +80,000 | $1.86 | 05/27/2026 | 05/29/2026 |
| Halawa Alaa | BUY | +80,000 | $1.86 | 05/27/2026 | 05/29/2026 |
| Piacquad David | BUY | +80,000 | $1.86 | 05/27/2026 | 05/29/2026 |
| Fust Matthew K | BUY | +80,000 | $1.86 | 05/27/2026 | 05/29/2026 |
| Burow Kristina | BUY | +80,000 | $1.86 | 05/27/2026 | 05/29/2026 |
| Milligan Michael Lee | SELL | -1,436 | $3.56 | 02/17/2026 | 02/19/2026 |
| BERNS PAUL L | SELL | -9,819 | $3.51 | 02/17/2026 | 02/19/2026 |
| Pinto Joshua | SELL | -5,967 | $3.54 | 02/17/2026 | 02/19/2026 |
| Aurora Daljit Singh | SELL | -6,165 | $3.56 | 02/17/2026 | 02/19/2026 |
| BERNS PAUL L | BUY | +1,650,000 | $2.33 | 01/08/2026 | 01/09/2026 |
| Pinto Joshua | BUY | +1,200,000 | $2.33 | 01/08/2026 | 01/09/2026 |
| Duncan Jason | BUY | +750,000 | $2.33 | 01/08/2026 | 01/09/2026 |
| Aurora Daljit Singh | BUY | +750,000 | $2.33 | 01/08/2026 | 01/09/2026 |
| Milligan Michael Lee | BUY | +350,000 | $2.33 | 01/08/2026 | 01/09/2026 |
| Aurora Daljit Singh | SELL | -114,703 | $2.68 | 11/11/2025 | 11/13/2025 |
| ARCH Venture Partners X, LLC | BUY | +1,915,700 | $2.61 | 10/27/2025 | 10/29/2025 |
| ARCH Venture Partners XII, LLC | BUY | +1,915,700 | $2.61 | 10/27/2025 | 10/29/2025 |
| Burow Kristina | BUY | +1,915,700 | $2.61 | 10/27/2025 | 10/29/2025 |
| Pinto Joshua | SELL | -3,000,000 | $1.69 | 05/28/2025 | 05/30/2025 |
| Halawa Alaa | SELL | -28,571 | $1.69 | 05/28/2025 | 05/30/2025 |